CoChat
Sign Up
Cited by 363Inflammatory Bowel DiseaseColorectal Cancer Screening and DetectionMicroscopic Colitis

Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease

Open access
Beaugerie, Laurent, Svrcek, Magali, Seksik, Philippe, Bouvier, Anne–Marie, Simon, Tabassome, Allez, Matthieu, Brixi, Hedia, Gornet, Jean–Marc +8 more·2013·Gastroenterology
DOI 10.1053/j.gastro.2013.03.044
Open this paper in CoChat — free accountOpen PDF

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2013.03.044

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Chronic inflammation and flares of disease are risk factors for CAC.

    “In agreement with this link, chronic inflammation and flares of disease have been identified as risk factors for CAC.37–39”

    From PU.1-driven Th9 Cells Promote Colorectal Cancer in Experimental Colitis Models Through Il-6 Effects in Intestinal Epithelial Cells (2022) · cites this paper as [38]

    The Background & Aims passage says chronic intestinal inflammation promotes carcinogenesis and identifies active intestinal inflammation as an established risk factor for colorectal cancer in IBD. It does not specifically identify disease flares as a risk factor; its reported cohort findings focus on long-standing extensive colitis. No page number is provided for the passage. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Part of this paper’s reference list could not be split into single entries.

Research works printed but not linked: 41

  1. Jess T, Gamborg M, Matzen P, et al. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 2005;100:2724-2729.
  2. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in pa- tients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012;10:639-645.
  3. Herrinton LJ, Liu L, Levin TR, et al. Incidence and mortality of colo- rectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology 2012;143:382-389.
  4. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-535.
  5. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 2011;140:1807-1816.
  6. Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990; 323:1228-1233.
  7. Torres J, Pineton de Chambrun G, Itzkowitz S, et al. Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther 2011; 34:497-508.
  8. Askling J, Dickman PW, Karlen P, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenter- ology 2001;120:1356-1362.
  9. Bansal P, Sonnenberg A. Risk factors of colorectal cancer in in- flammatory bowel disease. Am J Gastroenterol 1996;91:44-48.
  10. Mathy C, Schneider K, Chen YY, et al. Gross versus microscopic pancolitis and the occurrence of neoplasia in ulcerative colitis. Inflamm Bowel Dis 2003;9:351-355.
  11. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroen- terology 2004;126:451-459.
  12. Rutter MD, Saunders BP, Wilkinson KH, et al. Cancer surveillance in long-standing ulcerative colitis: endoscopic appearances help pre- dict cancer risk. Gut 2004;53:1813-1816.
  13. Lutgens MW, Vleggaar FP, Schipper ME, et al. High frequency of early colorectal cancer in inflammatory bowel disease. Gut 2008; 57:1246-1251.
  14. Jess T, Simonsen J, Jorgensen KT, et al. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 2012;143:375-381 e1.
  15. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005; 100:1345-1353.
  16. Baars JE, Looman CW, Steyerberg EW, et al. The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study. Am J Gastroenterol 2011; 106:319-328.
  17. van Schaik FD, van Oijen MG, Smeets HM, et al. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut 2011;61:235-240.
  18. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010;59:666-689.
  19. Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in in- flammatory bowel disease. Gastroenterology 2010;138:738-745.
  20. Velayos FS, Liu L, Lewis JD, et al. Prevalence of colorectal cancer surveillance for ulcerative colitis in an integrated health care delivery system. Gastroenterology 2010;139:1511-1518.
  21. Vienne A, Simon T, Cosnes J, et al. Low prevalence of colonoscopic surveillance of inflammatory bowel disease patients with long- standing extensive colitis: a clinical practice survey nested in the CESAME cohort. Aliment Pharmacol Ther 2011;34:188-195.
  22. Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006;130:1030-1038.
  23. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative dis- orders in patients receiving thiopurines for inflammatory bowel dis- ease: a prospective observational cohort study. Lancet 2009; 374:1617-1625.
  24. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011; 141:1621-1628 e5.
  25. Rutter MD, Saunders BP, Schofield G, et al. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut 2004;53:256-260.
  26. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classifi- cation of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749-753.
  27. Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000;47:251-255.
  28. Itzkowitz SH, Present DH. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:314-321.
  29. Van Assche G, Dignass A, Bokemeyer B, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis: special situations. J Crohns Colitis 2013;7:1-33.
  30. Hamilton SR, Vogelstein B, Kudo S, et al. Pathology and genetics. In: WHO Classification of Tumours of the Digestive System. Lyon, France: IARC Press, 2008:343-349. 2008.
  31. Lin DY, Wei LJ, Ying Z. Model-checking techniques based on cumu- lative residuals. Biometrika 2002;58:1-12.
  32. Manning AP, Bulgim OR, Dixon MF, et al. Screening by colonoscopy for colonic epithelial dysplasia in inflammatory bowel disease. Gut 1987;28:1489-1494.
  33. Nguyen GC, Bressler B. A tale of two cohorts: are we overestimating the risk of colorectal cancer in inflammatory bowel disease? Gastroenterology 2012;143:288-290.
  34. Choi PM, Zelig MP. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and preven- tion. Gut 1994;35:950-954.
  35. Svrcek M, Cosnes J, Beaugerie L, et al. Colorectal neoplasia in Crohn's colitis: a retrospective comparative study with ulcerative colitis. Histopathology 2007;50:574-583.
  36. Matula S, Croog V, Itzkowitz S, et al. Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin Gastroenterol Hepatol 2005;3:1015-1021.
  37. Connell WR, Lennard-Jones JE, Williams CB, et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative co- litis. Gastroenterology 1994;107:934-944.
  38. Fraser AG, Orchard TR, Robinson EM, et al. Long-term risk of ma- lignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther 2002;16:1225-1232.
  39. Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001; 134:89-95.
  40. Lashner BA, Provencher KS, Seidner DL, et al. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997;112:29-32.
  41. Mantzaris GJ, Christidou A, Sfakianakis M, et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's dis- ease. Inflamm Bowel Dis 2009;15:375-382. Received October 28, 2012. Accepted March 20, 2013. Reprint requests Address requests for reprints to: Prof Laurent Beaugerie, MD, PhD, Service de Gastroentérologie et Nutrition, Hôpital Saint-Antoine, 184 Rue du Faubourg Saint-Antoine, 75571 Paris Cedex 12, France. e-mail: laurent.beaugerie@sat.aphp.fr; fax: þ33 1 49 28 31

Cited by

Sorted by citations

Authors
Beaugerie, L., Svrcek, M., Seksik, P., Bouvier, A., Simon, T., Allez, M., Brixi, H., Gornet, J., Altwegg, R., Beau, P., Duclos, B., Bourreille, A., Faivre, J., Peyrin–Biroulet, L., Fléjou, J., & Carrat, F.
Affiliations
  • Assistance Publique – Hôpitaux de Paris (FR)
  • Inserm (FR)
  • Hôpital Saint Eloi (FR)
  • Centre Hospitalier Universitaire de Poitiers (FR)
  • Centre Hospitalier Universitaire de Nantes (FR)
Corresponding author
Beaugerie, Laurent
ORCID
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2013-07
Volume
145
Issue
1
Pages
166-175.e8
ISSN
0016-5085 (ISSN-L)
DOI
10.1053/j.gastro.2013.03.044
OpenAlex
W2031992003
Cited by
363
References
0
Citations by year
2026: 6 · 2025: 16 · 2024: 18 · 2023: 33 · 2022: 33 · 2021: 36 · 2020: 27 · 2019: 26 · 2018: 30 · 2017: 29 · 2016: 26 · 2015: 32 · 2014: 32 · 2013: 16
FWCI
23.45
Type
journal article
Language
en
Open access
Licence
Locations
  • Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Funders
  • Abbott
  • Merck
  • Vifor
  • Programme Hospitalier de Recherche Clinique National (AOM05157)
  • CESAME cohort
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
  • Health Sciences › Medicine › Epidemiology › Microscopic Colitis
Keywords
inflammatory bowel disease, Crohn's disease, colorectal cancer, high-grade dysplasia, thiopurine therapy, immunosuppressants, cancer risk, colorectal cancer prevention, standardized incidence ratio, hazard ratio
MeSH terms
Adult, Aged, 80 and over, Female, Humans, Male, Middle Aged, Precancerous Conditions, Prospective Studies, Risk, Colorectal Neoplasms, Inflammatory Bowel Diseases, Cohort Studies, Incidence, Multivariate Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review